🔎 Trials Near Me

Dachaigh › Leukemia biphenotypic geur › Minnesota

Sgrùdaidhean clionaigeach Leukemia biphenotypic geur ann an Minnesota

Tha 6 sgrùdaidhean airson Leukemia biphenotypic geur a’ lorg phàirtichean aig làraichean ann an Minnesota.

Bailtean ann an Minnesota

Teacsa sgrùdaidh oifigeil (Beurla)

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 3
365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 1/2
Suas gu aois 22 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04726241

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Rochester
A’ fastadhÌre 1/2
Aoisean 13 gu 90 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06533579

Allo HSCT Using RIC and PTCy for Hematological Diseases

  • Masonic Cancer Center at University of Minnesota, Minneapolis
A’ fastadhÌre 2
Suas gu aois 75 · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT05805605

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital and Clinics of Minnesota, Minneapolis
A’ fastadhÌre 1
Aoisean 1 gu 21 · Gach gnè · Air ùrachadh 6 Dùbh 2024 · NCT05476770

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.